Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT06888921

A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer (MAIA-ovarian)

An Adaptive Clinical Platform Trial to Evaluate the Safety and Efficacy of COM701 as Monotherapy or Combination Therapy as Maintenance Therapy in Participants With Relapsed Platinum Sensitive Ovarian Cancer (PSOC)

Sponsor: Compugen Ltd

Conditions Ovarian Cancer Ovarian Cancer Recurrent

Interventions COM701 Normal Saline

Updated 8 times since 2025 Last updated: Feb 26, 2026 Started: Jul 21, 2025 Primary completion: Mar 31, 2027 Completion: Mar 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Ovarian Cancer and Ovarian Cancer Recurrent and is currently actively recruiting participants. Compugen Ltd leads this study, which shows 8 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE1/PHASE2
Dec 2025 — Feb 2026 [monthly]

Recruiting PHASE1/PHASE2
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE1/PHASE2
Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE1/PHASE2
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE1/PHASE2

▶ Show 3 earlier versions

Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE1/PHASE2
May 2025 — Aug 2025 [monthly]

Recruiting PHASE1/PHASE2

Status: Not Yet Recruiting → Recruiting
Apr 2025 — May 2025 [monthly]

Not Yet Recruiting PHASE1/PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Compugen Ltd

Data source: Compugen Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ashdod, Israel , Augusta, United States , Besançon, France , Boston, United States , Charlotte, United States , Charlottesville, United States , Chicago, United States , Germantown, United States , Grand Rapids, United States , Haifa, Israel and 17 more locations